News

Captor Therapeutics announces positive proof-of-concept efficacy in-vivo data for its lead CT-03 program with strong antitumor activity at all doses tested

Captor Therapeutics opens State-of-the-Art Proteomics Lab

Captor Therapeutics strengthens its scientific team and prepares for the launch of clinical trials in 2023 with the appointment of Dr. Robert Dyjas as Director of Medical Affairs and Clinical Development

Captor Therapeutics Presents Compelling In Vivo Proof-of-Concept Data from CT-01 Program in Hepatocellular Carcinoma

Captor Therapeutics to attend the 11th Annual LifeSci Partners Corporate Access Event

Captor Therapeutics Presents 3Q’21 Financial Results and Provides a Business Update

Captor Therapeutics is one of the founders of the BioInMed - Polish Association of Innovative Medical Biotechnology Companies

Captor Therapeutics to Present at the 4th Annual Targeted Protein Degradation Summit